Reneo Pharmaceuticals
Focused on the development of therapies for patients with genetically defined orphan diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Reneo Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to developing therapies for rare genetic metabolic disorders. The company primarily focuses on conditions such as McArdle disease and primary mitochondrial myopathies (PMMs), which are characterized by severe muscle pain, weakness, and activity intolerance due to genetic mutations affecting muscle glycogen and mitochondrial function. Reneo's lead investigational compound, REN001, aims to enhance cellular energy metabolism by regulating genes involved in mitochondrial activity.
Reneo serves patients suffering from these rare diseases, operating in the biopharmaceutical market. The company's business model revolves around the research, development, and eventual commercialization of its therapeutic compounds. Revenue generation is anticipated through the successful approval and sale of these therapies, as well as potential partnerships and licensing agreements with larger pharmaceutical firms.
Keywords: rare diseases, genetic disorders, metabolic disorders, McArdle disease, mitochondrial myopathies, REN001, cellular energy, biopharmaceutical, clinical-stage, therapeutic development.